Colitis, Ulcerative
Conditions
Keywords
Janus Kinase Inhibitors
Brief summary
The treatment for Ulcerative Colitis (UC) aims to achieve and maintain remission and is usually lifelong and expensive. Current available medications are unable to break the cycle of chronic inflammation, and still a significant proportion of patients will fail to respond (primary non-response) or lose response over time (secondary non-response). There is now growing evidence that there is substantial interpatient variation in the composition of the inflammation associated network of immune cells. A deeper knowledge of the patient's alterations in the mucosal immune response would help identify key drivers of inflammation and select the appropriate therapy. By analyzing the changes in the composition of immune cells induced by Janus Kinase (JAK) inhibition, we aim to obtain a better insight into the mechanistic effects of JAK inhibition and the downstream effects. These mechanistic insights are needed to identifying potential responders and non-responders in the future.
Interventions
OTHERJAK inhibitor treatment
Standard care
Sponsors
Galapagos NV
Leiden University Medical Center
Study design
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
BASIC_SCIENCE
Masking
NONE
Intervention model description
Clinical practice protocol is followed. Additional biopsies and blood samples are taken.
Eligibility
Sex/Gender
ALL
Age
16 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
Age Ulcerative colitis active disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Multi-omics analyses of changes observed after JAK inhibition | 1 year |
Countries
Netherlands
Contacts
Primary ContactPhilip W Voorneveld, MD, PhD
Outcome results
None listed